



ORIGINAL ARTICLE

Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: A database study



Xavier Aldeguer^{a,*}, Antoni Sicras-Mainar^b

^a Hospital Universitari Doctor Josep Trueta, Girona, Spain

^b Badalona Serveis Assistencials, Badalona, Spain

Received 15 January 2015; accepted 8 April 2015

Available online 23 July 2015

KEYWORDS

Ulcerative colitis;
Productivity loss;
Indirect costs

Abstract

Objectives: To estimate the management of UC associated costs from the societal perspective in Spain.

Methods: Observational, longitudinal study with retrospective data collection based on reviews of outpatient health records. Socio-demographic, clinical and sick leave information was gathered. Patients diagnosed of UC between 2002 and 2012, older than 18 years, followed-up by a minimum of 12 months post diagnosis, with at least two clinical and use of resources data recorded, were included.

Results: 285 UC patients [51.2% men; 44.5 (SD: 15.6) years old; 88.4% without family history of UC; 39.3% proctitis; 5.6 (2.5) years disease follow-up] participated. More than half (65.6%) were active workers, 75.9% were on sick leave for reasons different from UC [mean 0.66 (0.70) times per year] during (mean) 28.43 (34.45) days. Only 64 patients were on UC-related sick-leaves, lasting (mean) 26.17 (37.43) days. Absenteeism due to medical visits caused loss of 29.55 (21.38) working hours per year. Mean direct and indirect annual cost per UC patient were €1754.10 (95%CI: 1473.37–2034.83) and €399.32 (282.31–422.69), respectively. Absenteeism was estimated at €88.21 (32.72–50.06) per patient per year, in which sick-leaves were the main component of indirect costs (88.2%). Age, UC family history, diarrhea at diagnosis, blood and blood-forming organs diseases and psychological disorders were the main predictors of indirect costs.

Conclusions: UC is a costly disease for the society and the Spanish National Healthcare System. Indirect costs imply a major burden by affecting the most productive years of patients. Further research is needed considering all components of productivity loss, including presenteeism-associated costs.

© 2015 Elsevier España, S.L.U. and AEEH y AEG. All rights reserved.

* Corresponding author.

E-mail addresses: xaldeguer@idibgi.org (X. Aldeguer), asicras@bsa.cat (A. Sicras-Mainar).

PALABRAS CLAVE

Colitis ulcerosa;
Pérdida de
productividad;
Gastos indirectos

Coste de la colitis ulcerosa desde una perspectiva social en el servicio de salud regional en España: un estudio de base de datos

Resumen

Objetivos: Evaluar la gestión de los gastos asociados a la CU desde la perspectiva social en España.

Métodos: Estudio observacional, longitudinal con recopilación de datos retrospectiva basado en reseñas de registros sanitarios ambulatorios. Se compiló información sociodemográfica, clínica y de bajas por enfermedad. Se incluyó a aquellos pacientes diagnosticados con CU entre 2002 y 2012, mayores de 18 años, con un seguimiento después del diagnóstico como mínimo a los 12 meses y con al menos 2 de los datos clínicos y de uso de recursos registrados.

Resultados: Participaron 285 pacientes con CU (51,2% hombres; $44,5 \pm 15,6$ años); 88,4% sin antecedentes familiares de CU; 39,3% proctitis; $5,6 \pm 2,5$ años de seguimiento de la enfermedad). Más de la mitad (65,6%) eran trabajadores en activo, un 75,9% estaban de baja por enfermedad por motivos ajenos a la CU (un promedio de 0,66 [0,70] veces al año) durante (media $\pm$ desviación estándar) $28,43 \pm 34,45$ días. Solo 64 pacientes estuvieron de baja por enfermedad relacionada con la CU, con una duración (media) de $26,17 \pm 37,43$ días. El absentismo ocasionado por las visitas al médico originó una pérdida de $29,55 \pm 21,38$ hs de trabajo al año. El promedio directo e indirecto del coste anual por cada paciente con CU fue de 1.754,10 € (IC95%, 1.473,37-2.034,83) y de 399,32€ (282,31-422,69), respectivamente. El absentismo se calculó en 88,21€ (32,72-50,06) por paciente al año, donde las bajas médicas son el mayor componente de los gastos indirectos (88,3%). La edad, los antecedentes familiares, la diarrea en el momento de diagnóstico, las enfermedades sanguíneas o de los órganos hematopoyéticos y los trastornos psicológicos fueron los principales factores predisponentes de los gastos indirectos.

Conclusiones: La CU es una enfermedad costosa para la sociedad y el Sistema Nacional de Salud español. Los gastos indirectos suponen una gran carga, al afectar a los años más productivos de los pacientes. Se precisa una mayor investigación que tenga en cuenta todos los componentes de la pérdida de productividad, entre otros los gastos asociados al presentismo laboral.

© 2015 Elsevier España, S.L.U. y AEEH y AEG. Todos los derechos reservados.

Introduction

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) caused by the continued inflammation of the colon mucosa which affects the rectum and a variable extension of the colon. UC may also have extra-intestinal manifestations that usually involve the skin, joints, the liver and eyes in nearly half of the affected individuals.^{1,2} Rectal bleeding is its cardinal symptom accompanied by diarrhea and rectal urgency. Fever, weight loss and abdominal pain are frequently present.³ Its diagnosis is based on differential diagnosis and on the clinical history, laboratory tests, imaging and endoscopic procedures with no specific biological marker existing for UC. Following the criteria of Montreal, UC can be classified in proctitis, left-side colitis or extended colitis according to its extension.^{3,4}

The highest incidence and prevalence of UC have been seen in North Europe and North America and the lowest in continental Asia.⁵ UC etiology is unknown and has been linked to genetic, immunological and environmental factors.⁶ In Western countries, the incidence and prevalence of UC has increased in the past decades up to 8–14/100,000 and 120–200/100,000 persons, respectively.^{7,8} In Spain, incidence rates have increased over the past years, whose values are closer to those obtained in Northern Europe.⁷

Differences in Spanish incidence rates (from 2 to 9.6 per 100,000 inhabitants per year) are due to methodological differences between studies.^{7,9}

UC is a chronic, incurable, lifelong disease that starts in young adulthood and continues throughout life. Regarding its social burden, most UC patients report frequent disturbing disease-related symptoms and have often visited their doctor or were absent from work due to UC problems over a year.¹⁰ Five years and twenty years subsequent to diagnosis, 10% and 30% of patients require surgery, respectively.¹¹ An impaired Health Related Quality of Life (HRQoL) has been directly related to the number of physician visits, work absenteeism, and a higher amount of undergone procedures ($p < 0.001$).¹²

Studies on the economic burden of the disease are scarce and its magnitude is little known in Spain. The extension of the disease critically determines the overall costs of its management while timely surgery seems to be associated with potential long term economic benefits.¹³ A Spanish study on the social and economic costs of IBD found that a patient with this disease costs 1730 € per year.¹⁴ While more detailed studies have been carried out on the direct costs of UC, and it has been shown that hospitalization, disease severity grade and disease extent correlate positively with the costs of illness, much less is known about the

indirect costs of UC patients.¹⁵ Regarding the indirect costs of the disease, it has been documented that UC patients can be either absent from work or being at work while having symptoms as many as twice the general population and that their productivity loss can be similar to that of patients with other chronic conditions, including arthritis, cancer or diabetes.¹⁶ Given the limited available information locally, this study estimates the costs associated to the management of UC from a social perspective in Spain.

Methods

Study design

An observational, longitudinal, retrospective study was conducted based on a review of outpatient health records from an administrative medical database including socio-demographic, clinical and sick leave data from patients of six primary care (PC) centers (Apenins-Montigalà, Morera-Pomar, Montgat-Tiana, Nova Lloreda, Martí-Julià and El Progrés) and one hospital (Hospital Municipal de Badalona), run by a health management organization (Badalona Serveis Assistencials S.A., Barcelona, Spain). Badalona Serveis Assistencial is a public organization with a private supply and is managed according to a business model, and its services portfolio is similar to that of most PC centers in Catalonia (Spain), with a decentralized management model and with integrated structural services. Badalona Serveis Assistencial takes care of 115,000 inhabitants of whom 17.1% are 64 or older and the assigned population is primarily urban.

The study population consisted of patients with diagnosis of UC (D94) in accordance with the International Classification PC-2 (ICPC-2)¹⁷ whose clinical and socio-demographic information were available in the database. To comply with inclusion criteria, patients had to (a) have a UC diagnosis which ICPC-2 code assigned between 1 January 2002 and 1 May 2012; (b) be older than 18 years of age; (c) have at least two clinical and resource use data recorded and (d) have 12 complete months follow-up since the diagnosis.

Ethical information

The protocol of the study was approved by the *Instituto Universitario de Investigación en Atención Primaria Jordi Gol* Clinical Research Ethics Committee.

Disease duration at study commencement

Time from diagnosis at study commencement was calculated as the difference in years between the documented date of UC diagnosis and the date of the last use of health care resources or sick leave recorded.

Use of health care resources and cost estimates

Health care resource utilization implied the number of general practitioner (GP) visits by all causes (UC related and non-related), number of referrals to the gastroenterologist, number of emergency room visits, number of hospitalizations and length of hospital stays (days);

number of laboratory tests performed by all causes, and number and type of drug prescriptions reimbursed by the Spanish National Health Service (NHS). Biological treatments were not recorded in the database.

Unitary costs of health care resources were obtained from the CatSalut published tariffs.¹⁸ Direct costs were estimated multiplying the unitary cost of each individual health care resource used by the corresponding frequency of its use. To estimate the annual cost per patient, the direct cost calculated for the observation period was divided into the corresponding number of follow-up years. All costs were expressed in Euros 2012.

Productivity loss and cost estimates

Only actively working patients were considered for estimating productivity loss associated to UC. Working days lost because of related and non-related UC sick leave, as recorded in the database, and medical visits in actively working individuals were taken into account. It was assumed that each medical visit implied the loss of half of a working day (4 h) for each employed person.

A longitudinal description of sick leave duration in the subgroup of patients with at least 9 years follow-up in the database was described. UC-related sick leaves were distinguished from the remaining causes.

Productivity loss was calculated as the sum of the yearly number of working days lost during sick leave and the time invested in medical visits (absenteeism) multiplied by the daily average inter-professional salary rate for Spain.¹⁹ To estimate the annual cost per patient, the indirect cost calculated for the observation period was divided into the corresponding number of follow-up years.

Statistical methods

A descriptive analysis was carried out in order to describe the socio-demographic and clinical characteristics of study subjects. Absolute and relative frequencies for qualitative variables, and mean and standard deviations (SD) for quantitative variables were calculated.

Cost results were expressed as mean, SD and 95% confidence intervals (CI). Additional information about the distribution of the sample according to indirect costs was obtained dividing the patients into two groups using an arbitrary Z score of 2 defined as follows: patients with a Z score >2, whose indirect cost exceeded the mean cost by 2 SDs, and patients with a Z score ≤2, whose mean indirect cost was below the mean by 2 SDs. This analysis allowed distributing the sample of patients into two UC patients' profiles by their cost estimates: patients with indirect costs closer to the mean, and patients with higher than the mean indirect costs.

A linear regression model was carried out to determine which variables have an effect on the indirect costs (dependent variable). Independent variables were demographic and clinical characteristics of patients. A stepwise procedure was implemented in order to select the best predictive set of variables according to Akaike information criteria.^{20,21} Statistical software R²² was used to perform the analysis and a significant level of 5% was considered.

Results

Demographic and clinical characteristics of the sample

A total of 385 UC patients were initially identified during the study observation period of whom 100 did not accomplish the inclusion criteria (14 patients were younger than 18 years old; 5 patients were diagnosed later than 1 May 2012; 81 patients did not have 12 complete months since UC diagnosis code had been assigned). The study sample corresponds to a total of 285 subjects. Disease follow-up duration varied between 2 and 10 years, with a mean of 5.6 years (SD: 2.5) (Fig. 1).

Half of patients were men (51.2%). Mean age was 44.5 (SD: 15.6) ranging from 18 to 84 years. More than half of the subjects were active workers (65.6%) at the time of study (Table 1).

With regard to the clinical characteristics of the sample (Table 2), patients were mostly non-smokers (68.4%) with no family history of UC (88.4%). The extent of UC was fairly similar amongst the studied individuals with extended colitis representing the least frequent expression of the disease (proctitis, 39.3%; left side, 36.5%; extended colitis, 24.2%). The most usual symptoms at diagnosis were rectal bleeding




Figure 1 Population follow-up duration of Ulcerative colitis.

Table 1 Demographic characteristics of study subjects.

Demographic characteristics		n (%)
Gender	Men	146 (51.2%)
	Women	139 (48.8%)
Age	18–44 years	157 (55.1%)
	45–64 years	85 (29.8%)
	65–84 years	43 (15.1%)
Labor situation	Active worker	191 (67.0%)
	Pensioner	94 (33.0%)
	Disability	17 (6.0%)
	Retirement	61 (21.4%)
	Early retirement	4 (1.4%)
	Widow pension	7 (2.5%)
	Unknown	5 (1.8%)
Place of residence	Badalona	279 (97.9%)
	Montgat/Tiana	6 (2.1%)

Bold text indicates most relevant results.

Table 2 Clinical characteristics of study subjects.

Clinical characteristics		n (%)
Smoking habit	Smoker	44 (15.4%)
	Non-smoker	195 (68.4%)
	Ex-smoker	46 (16.1%)
Extent of UC	Proctitis	112 (39.3%)
	Left sided colitis	104 (36.5%)
	Extended colitis	69 (24.2%)
UC family history	Yes	33 (11.6%)
	No	252 (88.4%)
Symptoms at diagnosis	Rectal bleeding	253 (88.8%)
	Diarrhea	228 (80.0%)
	Rectal urgency	169 (59.3%)
UC-related comorbidities	Fever	58 (20.4%)
	Pain	197 (69.1%)
	Weight loss	41 (14.4%)
	Ferropenic anemia	49 (17.2%)
	Pernicious anemia	8 (2.8%)
	Ocular pain	5 (1.8%)
	Pulmonary embolism	3 (1.1%)
	Osteoporosis	33 (11.6%)
Non-UC-related comorbidities	Glomerulonephritis	2 (0.7%)
	Urinary calculus	26 (9.1%)

Bold text indicates most relevant results.

(88.8%), diarrhea (80.0%), pain (69.1%) and rectal urgency (59.3%).

Ferropenic anemia was the most common UC-related comorbidity (17.2%) followed by osteoporosis (11.6%) and urinary calculus (9.1%). UC non-related comorbidities were mostly related to digestive and the musculoskeletal system and to skin pathologies (Fig. 2).

Resource utilization and direct cost

In regard to visits and hospitalizations for any cause, patients visited the GP 8.05 (SD: 5.81) times per year and were hospitalized less than once a year [mean: 0.62 (SD: 0.73)]. Patients who were admitted into hospital due to UC-related causes had a relatively short stay duration [mean: 4.13 (SD: 4.23) days per year] (Table 3). Less than one laboratory test per patient [mean 0.70 (SD: 0.55)] was performed per year. Other diagnostic tests, such as radiological images [mean 0.41 (SD: 0.36)] and colonoscopies [mean 0.33 (SD: 0.26)], were performed less frequently (Table 3). Anti-inflammatory drugs, such as corticosteroids and amino salicylic acid, were used by 74.0% of patients while immunosuppressive drugs were prescribed up to 21.4% (Table 4). Biological treatments were not recorded.

The mean direct annual cost of an UC ambulatory patient was €1754.10 (95%CI: 1473.37–2034.83) (Table 5). The main components of direct costs were hospitalizations (47.88%) and the prescribed pharmacological treatments (28.31%) for any cause (Fig. 3). 48% of medication cost was due to UC-related drugs (Fig. 4).




Figure 2 Registered ulcerative colitis non-related comorbidities.

Table 3 Annual use of health care resources.

Use of health care resources		Mean (SD)	n
Complementary tests	Laboratory tests	0.70 (0.55)	184
	Radiology tests	0.41 (0.36)	79
	Colonoscopy	0.33 (0.26)	79
	Polipectomy	0.66 (0.34)	3
	CT scan	0.19 (0.08)	11
	Gastroscopy	0.48 (0.36)	6
	Ecography	0.25 (0.23)	36
	Rectoscopy	0.23 (0.16)	2
	GP visits	8.05 (5.81)	261
Visits and hospitalizations	Gastroenterologist visits	2.43 (2.26)	96
	Mental health visits	0.85 (0.87)	6
	Hospitalizations (times)	0.62 (0.73)	118
	UC-related	0.60 (0.77)	43
	Non UC-related	0.51(0.55)	93
	Hospitalizations (stays)	4.18 (7.13)	118
	UC-related	4.13 (4.23)	43
	Non UC-related	3.39 (6.93)	93
	Emergency room visits	0.58 (0.53)	162
	UC-related	0.35 (0.31)	47
	Non UC-related	0.49(0.42)	155

Bold text indicates most relevant results.

Table 4 Distribution of patients according to UC-related medications.

UC-related medication	n (%)
Intestinal anti-inflammatory	211 (74.0%)
Corticosteroids	58 (20.4%)
Amino salicylic acid	204 (71.6%)
Immunosuppressive drugs	61 (21.4%)

Bold text indicates most relevant results.



Productivity loss and indirect cost

More than half of patients in the sample [65.6% ($n=191$)] were active workers; 145 of them had been on sick leave [mean 0.66 times (SD: 0.70) per year] for 28.43 days (SD: 34.45). Only 64 patients had a UC-related sick leave for 26.17 days (SD: 37.43). Absenteeism due to medical visits in these patients caused losing a mean of 29.55 working hours (SD: 21.38) per year (Table 6). Table 7 describes the clinical characteristics of patients with UC-related sick leave. 53.1% of patients were women. The mean age was 34.72 (SD: 9.46) years, mostly non-smokers (64.1%), with proctitis as subtype of the disease (48.4%) and without UC family

Table 5 Annual direct costs estimates.

Health resources cost	Mean (SD)	95%CI (lower limit-upper limit)
GP visits	€250.52 (203.79)	226.86–274.18
Gastroenterologist visits	€54.89 (116.70)	41.34–68.44
Mental health visits	€1.19 (11.23)	–0.11–2.49
Hospitalizations	€853.30 (2157.77)	602.79–1103.81
Emergency room	€61.07 (90.77)	50.53–71.61
Complementary tests	€50.06 (69.74)	41.96–58.16
Medication	€496.52 (574.63)	429.81–563.23
Direct cost	€1754.10 (2418.08)	1473.37–2034.83

Bold text indicates most relevant results.

**Figure 3** Direct and indirect costs main components associated to ulcerative colitis.**Figure 4** Population medication costs related to ulcerative colitis.**Table 6** Annual productivity loss caused by sick leave.

Productivity loss	Mean (SD)	n
Sick leave (number/year)	0.66 (0.70)	145
UC-related	0.38 (0.51)	64
Non UC-related	0.56 (0.51)	127
Sick leave (duration in days/year)	28.43 (34.45)	145
UC-related	26.17 (37.43)	64
Non UC-related	19.27 (22.47)	127
Absenteeism (working hours/year)	29.55 (21.38)	191


Bold text indicates most relevant results.

history (82.8%). Most common symptoms were rectal bleeding (92.2%), diarrhea (89.1%), pain (73.4%) and rectal urgency (68.8%). In relation to UC-related co-morbidities, ferropenic anemia (28.1%) and urinary calculus (14.1%) were the most frequent diagnosis.

For patients with at least a 9 years follow-up recorded in the database since the UC diagnosis ($n = 70$), the duration of sick leave in days for each year was described (Fig. 5). The

Table 7 Clinical characteristics of patients on sick leave.

Clinical characteristics of patients with sick leave		Patients with sick leave-due to any cause <i>n</i> (%)	Patients with sick leave-only due to UC <i>n</i> (%)
Smoking habit	Smoker	27(18.6%)	15 (23.4%)
	Non-smoker	96(66.2%)	41 (64.1%)
	Ex-smoker	22(15.2%)	8 (12.5%)
Extent of UC	Extended colitis	41(28.3%)	16 (25.0%)
	Left side colitis	42(29.0%)	17 (26.6%)
	Proctitis	62(42.8%)	31 (48.4%)
UC family history	No	125(86.2%)	53 (82.8%)
	Yes	20(13.8%)	11 (7.2%)
Symptoms	Rectal bleeding	135(93.1%)	59 (92.2%)
	Diarrhea	122(84.1%)	57 (89.1%)
	Rectal urgency	83(57.2%)	44 (68.8%)
	Fever	34(23.4%)	16 (25.0%)
	Pain	101(69.7%)	47 (73.4%)
UC-related co-morbidities	Weight loss	17(11.7%)	8 (12.5%)
	Ferropenic anemia	26(17.9%)	18 (28.1%)
	Pernicious anemia	4(2.8%)	3 (4.7%)
	Ocular pain	3(2.1%)	2 (3.1%)
	Pulmonary embolism	0(0.0%)	0 (0.0%)
	Osteoporosis	10(6.9%)	7 (10.9%)
	Glomerulonephritis	1(0.7%)	1 (1.6%)
	Urinary calculus	18(12.4%)	9 (14.1%)

**Figure 5** Population yearly reported sick leave days.

number of days due to sick leave per year for any cause was higher during the first, fourth and the eighth year while sick leaves caused by UC were more frequent in the first, fourth, seventh and eighth years. The non-parametric test equivalent to repeated measures ANOVA, Friedman test, showed statistically significant differences in duration of sick leave for any cause between years ($p=0.028$). In contrast, differences in duration of sick leave due to UC were not significant ($p=0.929$).

The mean annual indirect cost per patient was €399.32 (95%CI: 282.31–422.69). The main component of indirect cost was sick leave (88.25%) (Fig. 3). Absenteeism was estimated at €88.21 per patient per year (95%CI: 32.72–50.06) (Table 8).

Table 8 Annual indirect cost estimates.

Productivity loss cost	Mean (SD)	95%CI (lower limit-upper limit)
Sick leave	€311.11 (610.09)	240.28–381.94
Absenteeism	€88.21 (70.19)	32.72–50.06
Indirect cost	€399.32 (621.47)	282.31–422.69

Bold text indicates most relevant results.

The mean total annual cost of UC patients reached to €2153.42 (95%CI: 1809.97–2403.25), direct and indirect costs represented 81.5% and 18.5%, respectively.

Indirect cost subgroup analysis

Further information about the distribution of the sample of working patients according to its indirect cost was obtained by grouping the participants using a Z-score of 2, defined as the indirect cost exceeding the mean cost by 2 SDs. That division allowed two profiles of patients to be defined: patients with indirect costs locked to an average expenditure (Z-score ≤ 2) and patients with higher indirect cost estimates (Z-score > 2). Patients with a Z-score ≤ 2 (253 patients) and patients with a Z-score > 2 (19 patients) were described.

UC patients defined by their higher indirect costs (Z-score > 2) were mostly women (63.2% vs. 48.49%) and younger compared with Z-score ≤ 2 group patients [mean 44.7 (SD: 15.6) vs. mean 36.9 (SD: 9.5)]. UC disease duration (in years) was




Figure 6 Population clinical characteristics according to Z-score group.




Figure 7 Population use of resources according to Z-score group.

similar in both groups [mean 5.8 (SD: 2.5) vs. mean 5.7 (SD: 2.4)].

Also, differences in clinical characteristics between Z-score groups were observed (Fig. 6). Patients with Z-score >2 showed family history of UC (31.6% vs. 10.3%); smoking habits (31.6% vs. 15.0%); extended colitis subtype (57.9% vs. 21.7%) and UC symptoms as diarrhea (100.0% vs. 77.9%), rectal urgency (68.4% vs. 57.7%), and fever (31.6% vs. 19.0%) at diagnosis when compared with Z-score ≤2 patients. Consistent with previous characteristics, ferropenic anemia was the UC co-morbidity most frequently diagnosed in Z-score >2 patients group (42.1% vs. 13.3%).

Z-score >2 patients used more health resources compared with patients with Z-score ≤2 (Fig. 7), with higher costs due to hospitalizations [mean €949.50 (95%CI: 261.90–1637.11) vs. mean €822.93 (95%CI: 556.07–1089.79)] and

Table 9 Linear regression model: influence of demographic and clinical variables on indirect cost in UC patients.

Variables	Estimate	Std. Error	p-value
(Intercept)	574.62	186.39	0.0023**
Age	−10.25	3.08	0.0010**
UC family history	402.23	115.28	0.0006**
Non smoker	−149.29	115.07	0.1959
Ex-smoker	45.17	144.12	0.7543
Diarrhea	238.71	102.28	0.0206*
Weight loss	221.39	114.57	0.0547
Blood, blood forming organs, lymphatics, spleen	249.18	78.14	0.0016**
Circulatory pathology	−56.72	38.59	0.1431
Psychological disorders	132.27	41.37	0.0016**

Bold text indicates most relevant results.

* p-value < 0.05.

** p-value < 0.01.

medications [mean €724.31 (95%CI: 261.12–1187.50) vs. mean €467.33 (95%CI: 404.42–530.24)].

Factors influencing indirect costs

A linear regression model was conducted in order to assess the effect of socio-demographic (age and gender) and clinical variables (UC duration, smoking habit, extent of UC, UC family history, symptoms and ICPC-2 co-morbidities) on the indirect costs in UC patients (Table 9). A stepwise approach was followed.

Variables affecting costs ($p < 0.05$) were age, UC family history, the presence of diarrhea and the number of ICPC-2 co-morbidities related to blood-forming organ diseases and due to psychological disorders. The highest coefficient corresponded to UC family history which implied an increase on indirect costs of €402.23 per patient compared to patients with no UC family history. The second coefficient with the highest effect on indirect costs was the presence of diarrhea. Patients with diarrhea were significantly more expensive (€238.71) than patients without it. For each additional diagnosis of blood-forming organs and of psychological problems, indirect costs increased by €249.18 and €132.27, respectively, per patient. Age had a negative effect on indirect costs: for each year of older age, indirect costs decreased by €10.25 per patient.

Discussion

This study incorporates direct and indirect cost estimates in UC patients managed in a regional health care area in Spain. With regard to direct costs, findings are similar to those obtained in previous European publications. A study carried out in the United Kingdom estimated the direct costs of IBD, including UC patients, during a 6 months follow-up. Results showed that hospitalizations represented approximately 50% of direct costs followed by drugs prescriptions that corresponded to 25% of direct costs.¹⁵ Another study carried out in Israel and 8 European countries, including Spain, evaluated the expenditure on health care in Crohn's disease and UC patients during 10 years follow-up. The mean direct costs estimated for Spanish UC patients was €1524 (SD €4101) which were comparable to the results of the present study.²³ None of these studies included biological treatment costs.

More recent studies have included the use of biological therapies in the treatment of UC.^{24,25} The study from EpiCom group showed that 3% of UC patients from Western Europe received biological treatment as rescue therapy.²⁴ The other study carried out in Holland estimated the healthcare costs of IBD. Results showed that the use of biological therapies was the main costs driver, accounting for 31% of the total cost in UC patients.²⁵

In the studied sample, visits to emergency room and hospital admissions were infrequent with less than one admission per year per patient, whereas hospital stays were short, probably indicating that no surgery for UC took place during admissions. These results were consistent with those obtained from an Italian 10-year cohort study based on electronic database registries. Although UC patients had at least 1 or more hospitalization during the follow-up period, only 9.5% of admissions implied a surgical procedure while over 90% of them had a diagnostic and/or medical therapeutic purpose.²⁶

To project the direct costs of UC, it has to be considered that approximately one-third of patients with long-standing disease will require surgery during their lifetime, mainly due to medically refractory illness or to the development of colorectal dysplasia or colorectal cancer.^{27,28} Patients requiring hospitalization and surgery are among the most costly UC cases.²⁹ The armamentarium of medical therapies currently available to both induce and maintain remission represents

the second cost driver of the disease. In this study, medical treatment was the second component of direct costs despite biological treatment costs not being collected as no information was gathered directly from hospital databases.

Mean age of the studied population corresponded to individuals of working age, but with a slightly shorter duration of the disease than that observed in other European studies considering indirect costs.^{15,29,30} Indirect costs represented less than 20% of the total costs of the disease and implied productivity losses of about 26 days due to UC related sick leave and about 30 h of working time lost because of medical visits, per patient and year. These figures show the important economic burden of UC. Only a few European recent studies calculate indirect costs of UC patients representing 5%¹⁵ to 68%²⁹ of total costs, depending on the report. Bassi et al. carried out a 6-month study in the United Kingdom obtaining costs data from a postal questionnaire. The number of disease-related visits to a primary care doctor, out of pocket expenses, employment status and number of lost working days due to UC were collected. The results showed that 32% of employed patients with UC had loss of productivity with median annual indirect costs per patient amounting to €533 (£239).¹⁵ In Germany, the study carried out by Stark et al.²⁹ analyzed the use of healthcare facilities, medications, sick leave, out-of-pocket expenditures and long-term disability in UC patients using cost diaries. A total cost of €1015 (95%CI 832–1258) per patient during 4 weeks was calculated, 54% of which were indirect costs. Methodological disparities as well as the costs attached to the loss of productivity and to medicines paid out-of-pocket may easily explain the costs differences observed between these studies.²³

An additional description of participants was obtained using a Z-score which has shown to be useful to determine the distribution of a sample beyond a mean in cost studies.³¹ By selecting an arbitrary Z score, it is possible to identify groups of patients with higher costs who may potentially be different from other patients. It could then be argued that addressing the particular needs of these patients may contribute to reducing the mean annual costs of the disease. In the studied sample, patients with higher Z-score had showed more proportions of UC family history, smoking habits, extended UC subtype, ferropenic anemia, and diarrhea and fever at diagnosis. These patients represented higher health expenditures due to hospitalizations and medications.

When a regression model was conducted, factors with significant influence on indirect costs were age, smoking habit, family history of UC, psychological disorders and certain UC unrelated comorbidities. Amongst these features, family history of UC imposed the most significant effect on raising indirect costs. Comparison of these results with other studies cannot be conducted because regression model analysis considering only indirect cost has not been reported in the reviewed studies.^{15,29} Further insights are needed on the long term effects of these factors on the different components of the indirect costs of UC.

Findings reported for this study have to be interpreted in the context of its limitations inherent to its design, the nature of data coming from an administrative medical database and the costs used. Although a previous study carried out in Canada³² that compared self-reported and

administrative data in IBD patients showed high concordance between both sources of information for collecting data on medical resource use, more precise data gathering methods on productivity loss need to be put in place. For a more accurate description of the social consequences of UC from an economic point of view, reduced productivity of paid work (presenteeism) and reduced opportunities for unpaid activities (loss of leisure) need to be assessed. They are more difficult to measure and require directly asking the patient. Their knowledge would allow for a more precise estimation of the true burden of UC in society, particularly in the actively working population. Results apply only to a local area in Spain and extrapolation to the entire population should not be attempted. No data about the general population (without UC) were collected to compare the use of resources and productivity losses vs. UC patients. This information would give results on the real prospect of the costs of the UC. Along the same lines, to put the results in the context of the Catalan population, it would be of interest to compare the population seen in Badalona Serveis Assistencials organization with the rest of Catalan population with ulcerative colitis. Nonetheless, the findings depict the magnitude of UC burden even if patients with mild disease in the primary care setting are to be considered. Given the way data are collected in the database, only hospital admissions and emergency room visits, together with sick leave due to UC could be distinguished from all disease causes. Although this seems to be a fairly common limitation in this type of design,³³ average estimates for any disease cause had to be calculated.

In summary, UC is a costly disease for society and the healthcare system in Spain. Indirect costs imply a major burden by affecting individuals in the most productive years of their lives. Further research is needed taking into account all components of productivity loss including presenteeism, particularly in the mild and moderate forms of the disease, when medical treatment has a key role to play in keeping the illness under control.

Conflict of interests

The project was funded by AbbVie. AbbVie reviewed the final draft publication content for medical and scientific accuracy, and for intellectual property considerations, when applicable. The authors declare no conflicts of interests. The authors were responsible for all final content decisions and for the decision to submit the manuscript for publication.

Authors' contribution

X.A. and A.S. were expert advisors who participated in the interpretation of results, critically reviewed and drafted the manuscript.

Acknowledgements

The authors would like to thank Outcomes'10 for its collaboration in the development of the project and for the assistance in the critical revision of the manuscript and Dr. Xavier Calvet for the critical revision of the manuscript.

References

1. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol*. 2005;19 Suppl. A:5–36.
2. Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Díaz-Rubio M. Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal: diferencias entre la enfermedad de Crohn y la colitis ulcerosa. *Med Clin*. 2005;125:297–300.
3. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European Crohn's and Colitis Organisation (ECCO): European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. *J Crohns Colitis*. 2008;2:1–23.
4. Bermejo F, Guerra I, López-Sanromán. Colitis ulcerosa. *Medicine*. 2012;11:266–74.
5. Danese S, Fiocchi C. Ulcerative colitis. *N Engl J Med*. 2011;365:1713–25.
6. Hart AR, Luben R, Olsen A, Tjønneland A, Linseisen J, Nagel G, et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. *Digestion*. 2008;77:57–64.
7. López-Serrano P, Pérez-Calle JL, Carrera-Alonso E, Pérez-Fernández T, Rodríguez-Caravaca G, Boixeda-de-Miguel D, et al. Epidemiologic study on the current incidence of inflammatory bowel disease in Madrid. *Rev Esp Enferm Dig*. 2009;101:768–72.
8. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology*. 2011;140:1785–94.
9. Rivera R, de Sola C, Ubiña E, Pérez-Milla E, Fernández F, Navarro JM, et al. Incidencia y aspectos clínicoepidemiológicos de la colitis ulcerosa en el área de influencia del Hospital Costa del Sol. *Gastroenterol Hepatol*. 2007;30:7–10.
10. Holtmann MH, Galle PR. Current concept of pathophysiological understanding and natural course of ulcerative colitis. *Langenbecks Arch Surg*. 2004;389:341–9.
11. Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SP. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992–1993 cohort. *Inflamm Bowel Dis*. 2009;15:823–8.
12. Nurmi E, Haapaäki J, Paavilainen E, Rantanen A, Hillilä M, Arkkila P. The burden of inflammatory bowel disease on health care utilization and quality of life. *Scand J Gastroenterol*. 2013;48:51–7.
13. Holubar SD, Long KH, Loftus EV Jr, Wolff BG, Pemberton JH, Cima RR. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota. *Dis Colon Rectum*. 2009;52:1815–23.
14. Estudio prospectivo DELPHI (costes sociales y económicos de la enfermedad inflamatoria intestinal). Madrid: Nexus; 2005.
15. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. *Gut*. 2004;53:1471–8.
16. Fedorak RN, Wong K. Bridges. Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: incidence, prevalence, and direct and indirect economic impact. *Can J Gastroenterol*. 2010;24:651–5.
17. World Health Organization. International classification of primary care (ICPC-2). second ed; 2013. <http://www.who.int/classifications/icd/adaptations/icpc2/en/> [accessed June 2014].
18. Diari Oficial de la Generalitat de Catalunya; 2013. <http://portaldogc.gencat.cat/utisEADOP/PDF/6079/1227866.pdf> [accessed June 2014].
19. Boletín Oficial del Estado; 2012. <http://www.boe.es/boe/dias/2012/12/31/pdfs/BOE-A-2012-15766.pdf>

20. Akaike H. A new look at the statistical model identification. *IEE Trans Automat Control*. 1974;19:716–23.
21. Burnhan K, Anderson D. Model selection and multimodel inference: a practical information-theoretic approach. Springer-Verlag; 2002.
22. A language and environment for statistical computing. R Foundation for Statistical Computing; 2014. <http://www.R-project.org> [accessed June 2014].
23. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. *Aliment Pharmacol Ther*. 2010;31:693–707.
24. Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. *Gut*. 2014;63:588–97.
25. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNF α therapy: results from the COIN study. *Gut*. 2014;63:72–9.
26. Kohn A, Fano V, Monterubbianesi R, Davoli M, Marrollo M, Stasi E, et al. Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: a 10-year cohort study. *Dig Liver Dis*. 2012;44:369–74.
27. Cima RR, Pemberton JH. Medical and surgical management of chronic ulcerative colitis. *Arch Surg*. 2005;140:300–10.
28. Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, et al. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? *Dig Liver Dis*. 2007;39:617–25.
29. Stark R, König HH, Leidl R. Costs of inflammatory bowel disease in Germany. *Pharmacoeconomics*. 2006;24:797–814.
30. Blomqvist P, Ekblom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. *Scand J Gastroenterol*. 1997;32:1134–9.
31. Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, et al. European Collaborative Study on Inflammatory Bowel Disease: cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. *Gastroenterology*. 2006;131:719–28.
32. Longobardi T, Walker JR, Graff LA, Bernstein CN. Health service utilization in IBD: comparison of self-report and administrative data. *BMC Health Serv Res*. 2011;11:137.
33. Bickston S, Waters HC, Dabbous O, Tang B, Rahman MI. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. *J Manag Care Pharm*. 2008;14:352–62.